XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.3
REVENUES - Summary of Disaggregation of Revenues (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Disaggregation of Revenue [Line Items]        
Total revenues $ 7,051 $ 7,042 $ 20,002 $ 19,892
U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 5,017 4,928 14,253 13,622
Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 1,040 1,101 3,146 3,378
Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 993 1,013 2,603 2,891
Total product sales        
Disaggregation of Revenue [Line Items]        
Total revenues 6,994 6,978 19,864 19,650
Total product sales | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 4,985 4,900 14,196 13,482
Total product sales | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 1,017 1,064 3,069 3,281
Total product sales | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 992 1,013 2,599 2,887
Total HIV        
Disaggregation of Revenue [Line Items]        
Total revenues 4,667 4,487 13,482 12,422
Total HIV | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 3,807 3,661 10,949 9,906
Total HIV | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 519 541 1,568 1,653
Total HIV | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 341 285 965 863
Biktarvy        
Disaggregation of Revenue [Line Items]        
Total revenues 3,085 2,766 8,741 7,472
Biktarvy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 2,504 2,286 7,104 6,088
Biktarvy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 313 278 920 807
Biktarvy | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 268 201 717 577
Complera/Eviplera        
Disaggregation of Revenue [Line Items]        
Total revenues 34 43 104 142
Complera/Eviplera | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 13 20 40 56
Complera/Eviplera | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 18 21 55 76
Complera/Eviplera | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 3 3 9 10
Descovy        
Disaggregation of Revenue [Line Items]        
Total revenues 511 500 1,475 1,335
Descovy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 460 444 1,314 1,152
Descovy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 25 28 75 92
Descovy | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 26 28 86 91
Genvoya        
Disaggregation of Revenue [Line Items]        
Total revenues 503 600 1,544 1,764
Genvoya | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 433 502 1,305 1,441
Genvoya | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 47 71 157 220
Genvoya | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 23 27 81 103
Odefsey        
Disaggregation of Revenue [Line Items]        
Total revenues 343 374 1,011 1,077
Odefsey | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 257 276 754 763
Odefsey | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 74 86 223 278
Odefsey | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 11 12 33 36
Stribild        
Disaggregation of Revenue [Line Items]        
Total revenues 25 32 79 98
Stribild | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 18 22 57 68
Stribild | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 5 7 16 23
Stribild | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 2 3 6 7
Truvada        
Disaggregation of Revenue [Line Items]        
Total revenues 22 30 97 102
Truvada | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 15 24 71 77
Truvada | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 3 3 10 12
Truvada | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 4 2 16 13
Revenue share - Symtuza        
Disaggregation of Revenue [Line Items]        
Total revenues 131 130 390 388
Revenue share - Symtuza | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 96 85 278 251
Revenue share - Symtuza | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 32 40 101 126
Revenue share - Symtuza | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 3 4 10 10
Other HIV        
Disaggregation of Revenue [Line Items]        
Total revenues 13 12 41 45
Other HIV | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 10 1 24 11
Other HIV | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 3 6 11 20
Other HIV | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 0 5 6 15
Total Oncology        
Disaggregation of Revenue [Line Items]        
Total revenues 769 578 2,167 1,525
Total Oncology | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 462 409 1,354 1,067
Total Oncology | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 243 149 660 407
Total Oncology | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 65 20 153 52
Total Cell Therapy        
Disaggregation of Revenue [Line Items]        
Total revenues 486 398 1,402 1,040
Total Cell Therapy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 261 270 802 688
Total Cell Therapy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 181 111 491 308
Total Cell Therapy | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 45 17 109 44
Tecartus        
Disaggregation of Revenue [Line Items]        
Total revenues 96 81 272 217
Tecartus | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 64 60 179 160
Tecartus | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 27 20 83 56
Tecartus | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 4 1 11 2
Yescarta        
Disaggregation of Revenue [Line Items]        
Total revenues 391 317 1,130 823
Yescarta | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 197 210 624 528
Yescarta | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 154 91 408 253
Yescarta | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 40 16 99 42
Trodelvy        
Disaggregation of Revenue [Line Items]        
Total revenues 283 180 764 485
Trodelvy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 201 139 551 379
Trodelvy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 62 38 169 98
Trodelvy | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 21 3 44 8
Total Liver Disease        
Disaggregation of Revenue [Line Items]        
Total revenues 706 788 2,093 2,104
Total Liver Disease | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 376 413 1,051 1,056
Total Liver Disease | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 119 170 390 417
Total Liver Disease | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 211 204 652 631
Total HCV        
Disaggregation of Revenue [Line Items]        
Total revenues 438 524 1,335 1,371
Total HCV | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 260 283 751 745
Total HCV | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 85 143 294 332
Total HCV | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 93 98 289 294
Ledipasvir/Sofosbuvir        
Disaggregation of Revenue [Line Items]        
Total revenues 23 25 54 83
Ledipasvir/Sofosbuvir | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 17 8 29 27
Ledipasvir/Sofosbuvir | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 2 5 11 13
Ledipasvir/Sofosbuvir | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 4 12 14 43
Sofosbuvir/Velpatasvir        
Disaggregation of Revenue [Line Items]        
Total revenues 377 455 1,159 1,161
Sofosbuvir/Velpatasvir | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 215 241 643 629
Sofosbuvir/Velpatasvir | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 76 131 250 288
Sofosbuvir/Velpatasvir | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 85 84 266 244
Other HCV        
Disaggregation of Revenue [Line Items]        
Total revenues 38 44 123 127
Other HCV | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 28 34 80 88
Other HCV | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 7 7 33 31
Other HCV | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 3 2 10 7
Total HBV/HDV        
Disaggregation of Revenue [Line Items]        
Total revenues 269 264 758 733
Total HBV/HDV | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 116 131 299 311
Total HBV/HDV | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 34 28 96 85
Total HBV/HDV | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 119 106 363 337
Vemlidy        
Disaggregation of Revenue [Line Items]        
Total revenues 228 228 645 622
Vemlidy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 112 129 295 306
Vemlidy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 9 9 28 27
Vemlidy | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 106 90 322 289
Viread        
Disaggregation of Revenue [Line Items]        
Total revenues 21 22 62 69
Viread | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 4 2 4 4
Viread | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 5 5 17 17
Viread | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 12 15 40 48
Other HBV/HBD        
Disaggregation of Revenue [Line Items]        
Total revenues 20 14 51 42
Other HBV/HBD | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 0 0 0 1
Other HBV/HBD | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 19 13 50 41
Other HBV/HBD | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 0 0 0 0
Veklury        
Disaggregation of Revenue [Line Items]        
Total revenues 636 925 1,465 2,905
Veklury | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 258 336 607 1,179
Veklury | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 65 130 227 560
Veklury | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 313 458 630 1,166
Total Other        
Disaggregation of Revenue [Line Items]        
Total revenues 216 200 658 693
Total Other | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 82 80 236 275
Total Other | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 72 75 224 244
Total Other | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 62 46 199 174
AmBisome        
Disaggregation of Revenue [Line Items]        
Total revenues 115 105 381 380
AmBisome | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 12 9 39 48
AmBisome | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 63 63 192 192
AmBisome | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 39 33 150 140
Letairis        
Disaggregation of Revenue [Line Items]        
Total revenues 36 43 106 135
Letairis | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 36 43 106 135
Letairis | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 0 0 0 0
Letairis | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 0 0 0 0
Other        
Disaggregation of Revenue [Line Items]        
Total revenues 65 52 171 178
Other | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 34 28 91 91
Other | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 9 11 31 52
Other | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 23 13 49 35
Royalty, contract and other revenues        
Disaggregation of Revenue [Line Items]        
Total revenues 56 64 138 242
Royalty, contract and other revenues | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 32 28 57 140
Royalty, contract and other revenues | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 23 37 77 98
Royalty, contract and other revenues | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues $ 1 $ 0 $ 4 $ 4